Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors

Published:2013-09 Issue:2 Volume:11 Page:172-191
ISSN:1359-6349
Container-title:European Journal of Cancer Supplements
language:en
Short-container-title:European Journal of Cancer Supplements

Author:

Schmidinger Manuela

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference201 articles.

1. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

2. Motzer RJ, Hutson TE, Reeves J, et al. Randomized open-label phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (MRCC): results of the COMPARZ trial. 2012 ESMO Congress; 2012.

3. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma;Motzer;J Clin Oncol,2009

4. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med,2007

5. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial;Rini;Lancet,2011

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer;Cancer Immunology, Immunotherapy;2024-09-05

2. Physicochemical characterization and anti-angiogenesis activity of polysaccharides from Amauroderma rugosum, a medicinal and edible mushroom;International Journal of Biological Macromolecules;2024-08

3. Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis);Clinical Genitourinary Cancer;2024-06

4. The state of the art in secondary pharmacology and its impact on the safety of new medicines;Nature Reviews Drug Discovery;2024-05-21

5. Anti-Angiogenic Tyrosine Kinase Inhibitor-Related Toxicities Among Cancer Patients: A Systematic Review and Meta-Analysis;Targeted Oncology;2024-05-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3